SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Vertex Pharmaceuticals (MA) Release: National Health Service in England Funds KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People With a Specific Genetic Mutation (G551D)